Eidos Therapeutics, Inc.
EIDX evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Lead Asset:
- ag10 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for EIDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 1 pipeline candidate for Eidos Therapeutics, Inc..
Run Eidos Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eidos Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Eidos Therapeutics, Inc.'s lead drug candidate?
Eidos Therapeutics, Inc.'s most advanced tracked candidate is ag10 (Preclinical) for ATTR polyneuropathy (ATTR-PN).
Who is the CEO of Eidos Therapeutics, Inc.?
Neil Kumar is the chief executive officer of Eidos Therapeutics, Inc. (EIDX).
What therapeutic areas does Eidos Therapeutics, Inc. focus on?
Eidos Therapeutics, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.